In 2021, Idaho had the highest death rate from skin cancer, with an estimated 2.8 people out of 100,000 dying from melanoma. This statistic shows the death rate for melanoma of the skin in the U.S. in 2021, by state, per 100,000 population.

Mortality from skin cancers other than malignant melanoma (ICD-10 C44 equivalent to ICD-9 173). To reduce deaths from skin cancers other than malignant melanoma. Legacy unique identifier: P00658

In 2021, there were 8,224 deaths in the United States due to melanoma of the skin. The highest number of deaths within the given period due to melanoma was reported in 2013, with 9,394 deaths. This statistic describes the number of deaths due to melanoma of the skin in the United States from 1999 to 2021.

In 2021, the death rate due to melanoma of the skin in the United States was two per 100,000 population. The maximum rate in the given period was *** per 100,000 population. This statistic shows the death rate of melanoma of the skin in the United States from 1999 to 2021.

In 2022, Australia had the fourth-highest total number of skin cancer cases worldwide and the highest age-standardized rate, with roughly 37 cases of skin cancer per 100,000 population. The graph illustrates the rate of skin cancer in the countries with the highest skin cancer rates worldwide in 2022.

In 2021, Utah had the highest rate of skin cancer, with an estimated ** people out of 100,000 diagnosed with melanoma or another non-epithelial skin cancer. This statistic shows the incidence rate of skin cancer in the U.S. in 2021, by state, per 100,000 population.

As of 2021, non-Hispanic white people in the United States had the highest incidence rates of skin cancer among all races and ethnicities. Skin cancer is one of the most commonly occurring cancers in the world. Furthermore, the United States is among the countries with the highest rates of skin cancer worldwide. Skin cancer in the U.S. There are a few different types of skin cancer and some are more deadly than others. Basal and squamous skin cancers are more common and less dangerous than melanomas. Among U.S. residents, skin cancer has been demonstrated to be more prevalent among men than women. Skin cancer is also more prevalent among older adults. With treatment and early detection, skin cancers have a high survival rate. Fortunately, in recent years the U.S. has seen a reduction in the rate of death from melanoma. Skin cancer prevention Avoiding and protecting exposed skin from the sun (and other sources of UV light) is the primary means of preventing skin cancer. However, a survey of U.S. adults from 2024 found that around ******* never used sunscreen.

It was estimated that in 2025, around 5,470 men would die from melanoma of the skin, while 2,960 women would die from the disease. This statistic depicts the estimated number of skin cancer deaths in the U.S. in 2025, by gender.

The rate of skin cancer in the United States increased for both sexes from 1999 to 2021, with the rate for males consistently higher than that of females. This statistic shows the incidence rate of skin cancer in the U.S. from 1999 to 2021, by gender, per 100,000 population.

In 2022, it was estimated that almost 16.5 thousand people died from melanoma skin cancer in Europe, most of which were recorded in Germany with almost 6.2 thousand cases, while around 2.2 thousand deaths were registered in Italy. This statistic displays the estimated number of melanoma skin cancer deaths in European Union countries in 2022.

For current version see: https://data.sandiegocounty.gov/Health/2021-Non-Communicable-Chronic-Diseases/v7dt-rwpx

Basic Metadata *Rates per 100,000 population. Age-adjusted rates per 100,000 2000 US standard population.

**Blank Cells: Rates not calculated for fewer than 5 events. Rates not calculated in cases where zip code is unknown.

***API: Asian/Pacific Islander. ***AIAN: American Indian/Alaska Native.

Prepared by: County of San Diego, Health & Human Services Agency, Public Health Services, Community Health Statistics Unit, 2019.

Code Source: ICD-9CM - AHRQ HCUP CCS v2015. ICD-10CM - AHRQ HCUP CCS v2018. ICD-10 Mortality - California Department of Public Health, Group Cause of Death Codes 2013; NHCS ICD-10 2e-v1 2017.

Data Guide, Dictionary, and Codebook: https://www.sandiegocounty.gov/content/dam/sdc/hhsa/programs/phs/CHS/Community%20Profiles/Public%20Health%20Services%20Codebook_Data%20Guide_Metadata_10.2.19.xlsx

In 2022, the mortality rate from melanoma skin cancer in Northern Ireland was *** deaths per 100,000 for men and *** deaths per 100,000 for women. The overall mortality rate has climbed in Northern Ireland since 2000.

Rate: Number of deaths due melanoma cancer per 100,000 Population.

Definition: Number of deaths per 100,000 with malignant melanoma of the skin as the underlying cause of death (ICD-10 code: C43).

Data Sources:

(1) Centers for Disease Control and Prevention, National Center for Health Statistics. Compressed Mortality File. CDC WONDER On-line Database accessed at http://wonder.cdc.gov/cmf-icd10.html

(2) Death Certificate Database, Office of Vital Statistics and Registry, New Jersey Department of Health

(3) Population Estimates, State Data Center, New Jersey Department of Labor and Workforce Development

In 2018, Norway reported seven deaths from skin cancer per 100,000 population, the highest mortality rate in Europe. Slovenia followed with *** skin cancer deaths per 100,000, and then Sweden with a rate of *** skin cancer deaths On the other hand, there were *** deaths per 100,000 in Romania as a result of skin cancer.

Skin Cancer Market Outlook

The global skin cancer market size was valued at approximately USD 2.5 billion in 2023 and is projected to reach around USD 4.85 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2032. The market is experiencing steady growth due to factors such as increasing incidence rates of skin cancer, advancements in diagnostic and treatment technologies, and heightened awareness of skin cancer prevention and early detection. As a non-negligible public health concern, skin cancer's rising prevalence continues to drive the demand for effective diagnostic and treatment options, thereby propelling the market forward.

A significant growth factor for the skin cancer market is the increasing incidence of skin cancer cases worldwide. Over the past few years, there has been a noticeable surge in the number of skin cancer diagnoses, which can be attributed to factors such as heightened exposure to ultraviolet (UV) radiation from the sun and tanning beds, aging populations, and cultural trends favoring tanned skin. Additionally, genetic predispositions and the depletion of the ozone layer have further exacerbated the exposure risks. Public health initiatives have increased awareness around protective measures, yet the rise in cases continues, fueling the demand for more advanced diagnostic and treatment solutions.

Technological advancements in the field of dermatology are also significantly contributing to the growth of the skin cancer market. Innovations in diagnostic tools, such as dermatoscopy and advanced imaging solutions, have improved the accuracy and early detection rates of skin cancer. These technologies allow for non-invasive, cost-effective, and efficient identification of skin abnormalities, which are crucial for early intervention and improved patient outcomes. Furthermore, developments in treatment modalities, including targeted therapy and immunotherapy, offer more personalized and effective treatment options, enhancing the demand for cutting-edge solutions in the market.

Increased awareness and initiatives for early detection and prevention are pivotal drivers of market growth. Government bodies and non-profit organizations around the world have launched various campaigns to educate the public on the dangers of UV exposure and the importance of regular skin examinations. These initiatives have led to a rise in the number of individuals seeking medical advice and undergoing skin checks, thereby increasing the demand for dermatological healthcare services. Moreover, as people become more informed about the potential risks and signs of skin cancer, the market for diagnostic and preventive healthcare is expected to grow steadily.

The regional outlook of the skin cancer market indicates significant growth potential across various geographical areas. North America holds a substantial share of the market, driven by a high prevalence of skin cancer, advanced healthcare infrastructure, and robust investment in research and development. Europe follows closely with similar characteristics, including a strong emphasis on research and preventive healthcare measures. The Asia Pacific region is anticipated to exhibit the highest CAGR over the forecast period due to increasing healthcare awareness, rising disposable income, and the growing prevalence of skin cancer in countries such as Australia. Conversely, regions like Latin America, the Middle East, and Africa are expected to witness moderate growth, primarily due to lower awareness levels and limited access to advanced healthcare facilities.

Basal Cell Carcinoma Drug development is a crucial aspect of the skin cancer treatment landscape. As the most common type of skin cancer, basal cell carcinoma (BCC) often requires targeted therapeutic interventions to manage effectively. Recent advancements in pharmacology have led to the creation of innovative drugs that specifically target the molecular pathways involved in BCC proliferation. These drugs offer new hope for patients, particularly those with advanced or recurrent BCC, by providing more effective treatment options with fewer side effects compared to traditional therapies. The ongoing research and development in this area are expected to significantly impact the market, offering patients improved outcomes and expanding the arsenal of available treatments.

Type Analysis

The skin cancer market is segmented by type into basal cell carcinoma, squamous cell carcinoma, and melanoma, each repres

Supplementary Figure 1. Cutaneous Melanoma Age-adjusted Incidence Trends (2012-2021) Supplementary Figure 2. Cutaneous Melanoma Age-adjusted Mortality Trends (2013-2022) Journal of the American Academy of Dermatology

Legacy unique identifier: P00649

This data was taken from the R `lattice' package. The data is described in the package as follows: These data from the Connecticut Tumor Registry present age-adjusted numbers of melanoma skin-cancer incidences per 100,000 people in Connecticut for the years from 1936 to 1972. Format: A csv file has 37 observations on the following 2 variables. year: years 1936 to 1972. incidence: rate of melanoma cancer per 100,000 population.

IntroductionNon - melanoma skin cancer (NMSC) is a widespread malignant neoplasm affecting the skin globally. In China, over the past 30 years, the prevalence and incidence of NMSC have changed significantly, yet mortality rate (MR) data is scarce. The aim is to assess the MR data of NMSC patients worldwide from 1992 to 2021, analyze its temporal trends, and provide valuable epidemiological information for future prevention and management strategies of NMSC.MethodsUsing data from the Global Burden of Disease Study 2021 (GBD 2021), we analyzed crude mortality rate (CMR), age-standardized mortality rate (ASMR), and sex- and age-specific mortality trends, with temporal patterns assessed through longitudinal comparisons.ResultsThe MR for NMSC has shown an upward trend globally. From 1992 to 2021, both the CMR and ASMR for NMSC have increased substantially. The global ASMR has risen by approximately 30% during this period. Males have a higher ASMR compared to females, and the elderly population exhibits an accelerated and elevated ASMR trend for NMSC. In China, the mortality of NMSC is on the rise, with the current male MR exceeding that of females. Although the ASMR is projected to decline by 2030, the number of mortality cases is expected to increase, especially among males. The MR for NMSC shows a significant bias towards the elderly demographic.DiscussionThe increasing mortality of NMSC, both globally and in China, highlights the importance of effective prevention and management strategies. In addition to implementing prevention and intervention measures in susceptible populations, it is crucial to establish a screening framework for NMSC to detect minor symptoms in a timely manner. This will help in early diagnosis and potentially reduce the mortality rate associated with NMSC. Thank you for your editorial support.

In the years 2016 to 2020, over 99 percent of patients diagnosed with melanoma of the skin in England aged between 15 and 44 years of age would survive for at least one year, while patients this age had a five-year survival rate of nearly 97 percent. The survival rates for melanoma of the skin did generally fall if the patient was older when diagnosed.